Abstract. We report the case of an 8-yr-old girl with short stature. Her height was -2.65 SD and blood examination revealed hypokalemia (2.9 mEq/l), hypomagnesaemia, hypocalsiuria (Ca/Cr=0.0039) and metabolic alkalosis (pH 7.454, HCO 3 -24.9 mmol/l). For differential diagnosis between Gitelman's syndrome (GS) and Bartter syndrome (BS), we performed the loop diuretic furosemide (FUR) test and hydrochlorothiazide (HCT) double dose (2 and 4 mg/kg) test. Even the higher dose of HCT induced significantly lower increase of urinary Na and Cl excretions than the FUR. Growth hormone (GH) secretion tests (insulin and arginine) revealed GH deficiency. In addition to growth hormone injection, administration of Mg and spironolactone was started. After the replacement therapy started, the girl's height gain was improved (9.7 cm/yr) and her serum potassium became within the reference range. One year after GH replacement therapy was performed and GH replacement therapy was discontinued for two months, and GH secretion tests (insulin and arginine) showed GH deficiency again. We discussed previous reports of the clinical signs and test results of GS with regard to the relation between hypokalemia, hypomagnesemia and short stature.
Introduction
Patients with Gitelman's syndrome (GS) have mutations in the gene coding for thiazide-sensitive Na-Cl co transporter in the distal tubule (1) . A defect in this transporter can account for both the increase in magnesium excretion and potassium excretion and the marked decrease in Ca excretion (2) . GS is often not diagnosed until late childhood or even adulthood (2) . Most cases present some s y m p t o m s s u c h a s t e t a n y d u e t o hypomagnesaemia at the time of diagnosis (3). Yeun et al. (4) reported a clearance study by diuretic administration may be of diagnostic help in GS. Recently, we diagnosed a patient with short stature as having GS by evaluating the distal tubule function with two diuretics load test.
Case Report
An 8-yr-old girl visited our hospital for evaluation of short stature. She had marked short stature (-2 SD) from her infancy. Her height was -2.65 SD, obesity index was -10%, and blood examination revealed hypokalemia (2.9 mEq/l), hypomagnesaemia, hypocalsiuria (Ca/Cr=0.0039) Vol.14 / Suppl 24 and metabolic alkalosis (pH 7.454, HCO 3 -24.9 mmol/l). Growth hormone (GH) secretion tests (insulin and arginine) revealed GH deficiency (GHD). The girl was referred to our hospital for evaluation of hypokalemia. At the admission to our hospital, she was normotensive with normal renal function (BUN 13 mg/dl, serum creatinine 0.36 mg/dl). She showed serum potassium levels of 2. Table 1 ). The patient showed normal calcium and phosphorus levels, and ultrasonography findings of the kidney were normal. No family history of GS or related disorders was found, and the patient had no past medical history or the medical prescription including diuretics.
For differential diagnosis between GS and Bartter syndrome(BS), we performed the loop d i u r e t i c f u r o s e m i d e ( F U R ) t e s t a n d hydrochlorothiazide (HCT) double dose (2 and 4 mg/kg) test. The data showed Table 2 . Even the higher dose of HCT induced significantly lower increase of urinary Na and Cl excretions than FUR.
After the diagnosis, administration of spironolactone 30 mg/day and MgPO 4 1 g/day and GH injection were started. After the replacement therapy started, her height gain improved. Height velocity in the first year of treatment was 9.7 cm/ yr. Then, GH secretion tests (insulin and arginine) were done again after GH administration had been stopped for 2 months. At that time, serum potassium level was 4.3 mEq/l and serum magnesium level was 1.7 mg/dl. The result again showed GHD. 
Discussion
We diagnosed a patient with short stature as having GS by the distal tubule function with FUR and HCT loading tests, but we did not investigate the genotype of GS. The functional activity of the renal thiazide-sensitive Na-Cl co transporter is deficient in GS. Giacomo (5) mentioned diuretic administration may be of diagnostic help in GS. On the other hands, there have been phenotype variability and phenotype overlap between GS and BS. Jeck (6) reported three unrelated patients presenting with typical laboratory findings of GS did not have abnormality in SLC12A3. Instead, all of three patients were found to carry previously described mutations of the CLCNKB gene. A Japanese family with GS was found to carry heterozygous mutation in the SLC12A3 gene r e v e a l e d o n l y h y p o k a l e m i a b u t n o t hypomagnesaemia nor hypocalciurea (7). Furthermore, there are two different types of genetic transmission of GS, one autosomal recessive and one autosomal dominant with high phenotype variability. This genetic heterogeneity is associated with a different clinical expression with frequent tetanic episodes and lower plasma potassium and magnesium levels in the autosomal recessive form (8) .
About 18% of patients with GS have a height below -2 SD (9). Hypokalemia decreases response of GH to GRH. Evidence that potassium deficiency induces growth retardation through reduced circulating levels of growth hormone and insulinlike growth factor I was reported (10). Ko C.W. et al. (11) reported a case of GS whose height gain and hypomagnesaemia were improved by administration of GH. Although the second growth hormone secretion tests (insulin and arginine) again showed again GHD in our case, serum potassium levels and magnesium level were normal. Bettinelli (12) reported the case with empty sella presenting hypokalemia, mild hypomagnesemia, and mild hypocalciuria (GS). We need to re-evaluate whether our patient really requires GH treatment. 
